BioCryst Pharmaceuticals, Inc

BCRX NASDAQ
BCRX
BioCryst Pharmaceuticals, Inc NASDAQ
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E

BCRX financial statements

An in-depth look to BioCryst Pharmaceuticals, Inc operating, investing, and financing activities

BCRX free cash flow for Q1 22 is -78.21M USD. For 2021, BCRX free cash flow was -144.54M USD and operating cash flow was -142.16M USD.

TTM
Cash from operating activities
Funds from operations
Changes in working capital
Cash from investing activities
Purchase/sale of business, net
Purchase/sale of investments, net
Capital expenditures
Other investing cash flow items, total
Cash from financing activities
Issuance/retirement of stock, net
Issuance/retirement of debt, net
Total cash dividends paid
Other financing cash flow items, total
Free cash flow